Mirum Pharmaceuticals, Inc.
General ticker "MIRM" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.6B (TTM average)
Mirum Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 59.5%.
Estimated limits based on current volatility of 3.2%: low 89.13$, high 94.97$
Factors to consider:
- Total employees count: 322 (+22.0%) as of 2024
- US accounted for 81.4% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Commercialization challenges, Market competition, Operational and conduct risks, Manufacturing disruptions, Regulatory and compliance
- Current price 79.0% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [29.14$, 57.45$]
- 2025-12-31 to 2026-12-31 estimated range: [25.18$, 50.87$]
Financial Metrics affecting the MIRM estimates:
- Negative: with PPE of -22.4 at the end of fiscal year the price was high
- Negative: negative Operating income
- Positive: 19.35 < Shareholder equity ratio, % of 33.64 <= 42.53
- Positive: Interest expense per share per price, % of 0.73 <= 0.74
- Positive: -14.19 < Investing cash flow per share per price, % of -4.57
Short-term MIRM quotes
Long-term MIRM plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $77.06MM | $186.37MM | $336.89MM |
| Operating Expenses | $208.28MM | $295.53MM | $424.49MM |
| Operating Income | $-131.22MM | $-109.15MM | $-87.61MM |
| Non-Operating Income | $-10.85MM | $-53.27MM | $0.69MM |
| Interest Expense | $15.98MM | $15.11MM | $14.31MM |
| R&D Expense | $106.84MM | $102.61MM | $140.63MM |
| Income(Loss) | $-142.07MM | $-162.42MM | $-86.91MM |
| Taxes | $-6.41MM | $0.99MM | $1.03MM |
| Profit(Loss)* | $-135.66MM | $-163.41MM | $-87.94MM |
| Stockholders Equity | $142.04MM | $248.67MM | $225.64MM |
| Inventory | $5.57MM | $22.31MM | $22.40MM |
| Assets | $352.91MM | $646.62MM | $670.75MM |
| Operating Cash Flow | $-120.14MM | $-70.94MM | $10.32MM |
| Capital expenditure | $0.28MM | $20.11MM | $0.99MM |
| Investing Cash Flow | $7.70MM | $-107.20MM | $-90.12MM |
| Financing Cash Flow | $109.09MM | $336.60MM | $17.70MM |
| Earnings Per Share** | $-4.01 | $-4.00 | $-1.85 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.